title: Conversion to sirolimus in renal transplant patients with tumors.
abstract: BACKGROUND
  Conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) is an option for renal transplant patients who develop a tumor. This strategy, however, may be associated with an increased risk of rejection.
  
  
  OBJECTIVE
  We sought to evaluate a series of renal transplant patients who underwent conversion from CNI to SRL because they developed a tumor during the posttransplant period.
  
  
  METHODS
  This prospective study of 29 patients included 2 patients with skin cancer (1 melanoma and 1 squamous cell carcinoma) and 27 patients who developed other tumors: lung (n = 6), prostate (n = 4), lymphoma (n = 2), colon adenocarcinoma (n = 2), kidney (n = 2), Kaposi sarcoma (n = 2), urothelium (n = 1), parotid (n = 1), larynx (n = 1), gastric (n = 1), breast (n = 1), tongue (n = 1), liver (n = 1), xanthoastrocytoma (n = 1), and aggressive angiomyxoma of the perineum (n = 1).
  
  
  RESULTS
  CNI were withdrawn in 28 patients and reduced in the remaining patient. Renal function was better when CNI were rapidly or abruptly suspended, with maintenance of cyclosporine (CsA) + SRL for more than 3 months being especially detrimental. Proteinuria worsened in patients whose preconversion levels were >0.5 g/d, particularly those treated with CsA. There was no episode of rejection.
  
  
  CONCLUSIONS
  SRL is a promising option for the management of posttransplant tumors. The switch in immunosuppression should be undertaken quickly, especially in patients under treatment with CsA.
authors.affiliation: Nephrology Department, Hospital Clinico San Carlos, Madrid, Spain. sanchezfruct@telefonica.net
authors.forename: A
authors.initials: A
authors.lastname: Sánchez-Fructuoso
authors.forename: J
authors.initials: J
authors.lastname: Conesa
authors.forename: I
authors.initials: I
authors.lastname: Perez Flores
authors.forename: N
authors.initials: N
authors.lastname: Ridao
authors.forename: N
authors.initials: N
authors.lastname: Calvo
authors.forename: D
authors.initials: D
authors.lastname: Prats
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez
authors.forename: A
authors.initials: A
authors.lastname: Barrientos
mesh_terms: D003404:Creatinine / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology*; D009369:Neoplasms / Q000145:classification / Q000453:epidemiology*; D011183:Postoperative Complications / Q000453:epidemiology; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D003404:Creatinine; D020123:Sirolimus